Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity

Ho Sup Lee; Chang Bae Son; Seong Hoon Shin; Yang Soo Kim

doi:10.4143/crt.2008.40.3.121

Articles

Page Path: HOME > Cancer Res Treat > Volume 40(3); 2008 > Article

Original Article Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity: Ho Sup Lee, M.D., Chang Bae Son, M.D., Seong Hoon Shin, M.D., Yang Soo Kim, M.D.; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2008;40(3):121-126.
DOI: https://doi.org/10.4143/crt.2008.40.3.121
Published online: September 30, 2008

Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.

Correspondence: Yang Soo Kim, Department of Internal Medicine, Kosin University Gospel Hospital, 34, Amnam-dong, Seo-gu, Busan 602-702, Korea. (Tel) 82-51-990-6107, (Fax) 82-51-990-3010, yas@ns.kosinmed.or.kr

• Received: July 5, 2008 • Accepted: August 7, 2008

10,495 Views
80 Download
35 Crossref

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

Abstract

Purpose
Anthracycline can effectively treat hematologic malignancies, but has significant risk of cardiotoxicity. We measured the clinical correlation between brain natriuretic peptide (BNP) and anthracycline-induced cardiotoxicity.
Materials and Methods
Between March 2005 and March 2007, 86 patients with acute leukemia, malignant lymphoma, or multiple myeloma receiving systemic chemotherapy with anthracycline were enrolled in the Department of Hemato-oncology, Kosin University Gospel Hospital. We investigated the relationship between BNP level and cardiotoxicity through echocardiography, electrocardiography, BNP levels, and symptoms of heart failure at each chemotherapy cycle.
Results
Of the 86 participants (mean age, 48.5 years; range 20~65 years), cardiotoxicity developed in 21 patients (24.4%), with 2 patients showing arrhythmia only, 17 patients with transient aspects of heart failure, and 2 patients with chronic heart failure. Cardiotoxicity related to serum BNP level, age, cumulative dose of anthracycline, accompanying chronic disease, and elevated level of troponin-I. Heart failure was more common if BNP levels reached 100 pg/ml at least once.
Conclusions
The clinical correlation between BNP and cardiotoxicity was significant in patients with systemic anthracycline chemotherapy. A prospective clinical trial will be needed to identify the causal relationship between serum BNP level and cardiotoxicity.
Key words: Hematologic neoplasms, Anthracycline, BNP, Cardiac toxicity

INTRODUCTION

Anthracyclin chemotherapeutic agents such as Doxorubicin (adriamycin) and epirubicin show strong activity to kill malignant cells, and thus they have been used for various kinds of malignant diseases. Nevertheless, cardiotoxicity induced by anthracyclin may cause long term side effects after treatment, hence, it has been considered to be an important problem (1,2). In other words, in cases of malilignant lymphoma, acute leukemia, multiple myeloma and other hematological tumors or breast cancer among solid tumors that could be completely cured or long term survival is possible by the treatment with chemotherapy including anthracyclin, but heart failure developed during treatment or after treatment is a severe side effect that threatens the life of patients and deteriorates quality of life (3-8).

Cardiotoxicity induced by anthracyclin is associated with the cumulative dose of drug, and in addition, it has been reported that in cases accompanying other risk factors such as age, female and others, the possibility of developing cardiotoxicity is high (9,12,13). Thanks to the development of diverse chemotherapeutic agents and the improvement of adjuvant therapies, malignant diseases including numerous hematological diseases could be completely cured (7).

Therefore, to predict and to prevent the long term toxicity caused by chemotherapeutic agents accompanied after treatment are important, and strategies for them are considered to be required. For the diagnosis of cardiotoxicity including heart failure, methods using ultrasonography has been used widely presently, and it is useful for the diagnosis of cases developed complications, nonetheless, it does not show satisfactory results for early detection (10). Brain natriuretic peptide (BNP) is a type of cardiac neurohormone secreted by the ventricles due to the increase of ventricular volume and pressure, elevation of serum concentration of BNP has been known to be significantly correlated to the left ventricular end diastolic pressure as well as pulmonary capillary wedge pressure in heart failure patients (14). Pertinent to this, since serum concentration of BNP reflects left ventricular dysfunction, it has been applied to the diagnosis as well as treatment of heart failure patients and to predict prognosis (16,17). Anthracyclin has been also known to induce the degeneration of ventricular muscles and thus to show congestive heart failure features (5). Therefore, in this study, in patients administered anthracyclin chemotherapeutic agents, the correlation of the plasma concentration of BNP and cardiac complications was examined by measuring plasma BNP regularly.

MATERIALS AND METHODS

1) The subjects

The subjects were acute leukemia, malignant lymphoma and multiple myeloma cases admitted to the department of Hematooncology, Kosin University Gospel Hospital from March 2005 to March 2007, and treated with chemotherapy including anthracyclin. As age, the subjects were patients between 20 years and 65 years, and cases with the past history of cardiac diseases, patients with cor pulmonale, patients with brain metastasis, and patients with liver failure (serum ALP/AST > more than 2 times of normal values) were excluded. The follow up period was from 6 months to 2 years.

2) Methods

(1) Echocardiographic test

For trans-thoracic echocardiographic test, the sonos 5,500 equipment (Hewlett-Packard, Andover, Massachusetts) was used. As echocardiographic test, according to the method recommended by the American Society of Echocardiography, the M type, two dimensional echocardiography and Doppler echocardiography were performed, and by the M type echocardiography, the thickness of the ventricular septum, the thickness of the left ventricular posterior wall, the diameter of the left ventricle at the end-diastolic phase, the diameter of the left ventricle during the end-systolic phase, and the diameter of the right and left atrium were measured, and applying the modified Simpson method, the ejection fraction of the left ventricle was measured.

(2) Measrement of Brain Natriuretic Peptide (BNP) and troponin I (Tn-I)

In all the subject patients, they were measured prior to each treatment cycle. The concentration of plasma BNP and troponin-I was measured by collecting the whole blood using a test tube containing ethylon deamine tetraacetic acid (EDTA). BNP plasma value was quantitatively examined by chemiluminescence immunoassay (CLIA) using the Triage® BNP kit, the lower limit of measurement was 5 pg/ml, and the normal maximal value was 100 pg/ml. Troponin-I was measured chemiluminescence immunoassay (CLIA) using the Beckman Coulter Access AccuTnI kit, the lower limit of measurement was 0 ng/ml, and the normal maximal value was 0.2 ng/ml.

3) Statistical analysis

For the statistical analysis of the data, the SPSS 14.0 program was used, continuous variables were presented as the median value, the upper limit and the lower limit, and non-continuous variables were presented as the frequency and percent. In univariate analysis, to examine the correlation of clinical factors including BNP with cardiac accident, continuous variables were analyzed using Mann-Whitney test, and non-continuous variables were analyzed using chi-square test. In multivariate analysis, factors showing the statistical correlation with P value less than 0.1 in univariate analysis were analyzed by logistic regression analysis, and factors showing P value less than 0.05 were defined to be statistically significant. To validate echocardiographic index mediating effects on plasma BNP concentration, correlation analysis was performed, and as the method of entered analysis, entered multiple regression analysis was used.

RESULTS

1) Clinical characteristic of the subject patients

The subject patients were total 86 cases, their mean age was 48.5 years, and between 20 years and 65 years. Male patients were 49 cases (57%), and as underlying malignant diseases, malignant lymphoma patients were 59 cases (non-Hodgkins lymphoma was 52 patients, Hodgkins was 7 patients), which was most prevalent, acute leukemia was 17 patients, and multiple myeloma patient was 10 patients. Patients with associated chronic diseases were 33 patients of 86 patients (38.4%), patients accompanying hypertension were 7 cases, patients with diabetes were 8 cases, chronic hepatic disease was 6 cases, chronic renal failure was 3 cases, and patients with diabetes and hypertension simultaneously were 4 cases. In regard to anthracyclin chemotherapeutic agents administered, doxorubicin was 67 patients of 86 patients, which was used most prevalently, and in general, the cumulative anthracyclin dose was 300 mg/m² (Table 1).

2) The frequency of the manifestation of cardiotoxicity

We defined the diagnosis of heart failure based on the Framingham diagnosis standard (it could be diagnosed when abnormality in more than one category among the major criteria such as nocturnal dyspnea, rale, cardiomegaly, acute pulmonary edema, cervical venous dilation, etc., and satisfy more than two minor criteria such as dyspnea during exercise, nocturnal cough, peripheral edema, hepatomegaly, pleural effusion, etc.25 Among the entire patients, cases whose electrocardigram was changed to abnormal were 20 patients (23.3%), cases developed cardiotoxicity were 21 patients (24.4%), cases showing only cardiac failure without symptoms of aneurysm or hypotension were 15 patients, which was most prevalent, and cases showing only aneurysm symptoms on electrocardiogram were 2 patients. Cases showing hypotension together with cardiac failure were 3 patients, and among them, 1 patient expired. Among 19 patients shown heart failure, all patients excluding 2 patients showed temporary heart failure, they were treated with diuretic and nitrate agents, and symptoms were improved within one month in most cases, and 2 patients showed chronic outcomes, and thus continuous treatments were required (Table 2).

3) The change of plasma BNP concentration and echocardiographic abnormality

In the comparison of the maximal increased value of plasma BNP concentration of patients developed cardiotoxicity during the treatment of chemotherapy included Anthracyclin and other patients, in cases developed cardiotoxicity, the maximal value of BNP concentration was significantly elevated, and the maximal value of the left ventricular mass measured by echocardiography during the administration of anthracyclin was also significantly increased. The mean of the minimal value of left ventricular avascularization during chemotherapy of cases developed cardiotoxicity showed significantly lower values than cases without the development. Here, as cardiotoxicity accident, among the four types, heart failure, aneurysm, heart failure and shock, and heart failure and aneurysm, the subjects were cases developed only heart failure, because besides heart failure, the incidence of the cardiotoxicity accident aneurysm, shock, etc. were too low, and thus they were considered to be statistically not significant and excluded, and the result of the final analysis showed that plasma BNP concentration and left ventricular mass, and left ventricular avascularization rate were all showed a correlation to heart failure (Table 3).

4) The relationship of plasma BNP concentration and the follow up cardiac events (Table 4 and Table 5)

The development of cardiotoxicity based on the presence or absence of the development of aneurysm, heart failure, and shock was examined, and it was found to be developed in 21 patients (Table 2), and among them, 19 patients showed cardiac failure, and in univariate analysis and multivariate analysis, cardiotoxicity event developed during chemotherapy was limited to heart failure among the types of the development of cardiotoxicity. In univariate analysis, factors related to the development of heart failure were cases with the elevation of plasma BNP concentration (p<0.001), cases that ventricular avascularization rate was decreased to less than 50% (p<0.001), cases accompanying chronic diseases (p=0.012), cases showing abnormalities on echocardiogram (p<0.001), and cases that troponin-I was increased to more than 0.2 ng/ml (p=0.002). In addition, in cases older than 60 years, although it was not statistically significant, the possibility of the development of cardiotoxicity was shown to be high (p=0.066).

In multivariate analysis, as factors associated with the development of cardiotoxicity, the elevation of plasma BNP concentration, abnormal echocardiogram, and the elevation of troponin-I were confirmed to be statistically significantly associated.

DISCUSSION

Chemotherapeutic agents used for chemotherapy may cause permanent injury of normal tissues as well as diverse organs in human body, such side effects may become problems particularly in diseases that long term survival is possible, and even if malignant diseases were cured, due to sequelae impairment, it may cause the deterioration of quality of life. Particularly, the myocardium is formed by cells with limited regeneration ability, and thus if injured once, it shows permanent dysfunction, hence, if side effects of chemotherapy occurred, it could be considered to be fatal (1-8).

The effect of chemotherapeutic agents on the myocardium could be predicted, nonetheless, occasionally, it could not be predicted in some cases. The anthracyclin daunorubicin, doxorubicin, epirubicin, and idarubicin induce myocardial degeneration in association with the cumulative drug dose, and in such cases, it causes acute or subacute cardiotoxicity, and it may cause chronic complications (9).

Acute toxicity induced by anthracyclin chemotherapeutic agents are supraventricular tachycardia, ventricular tachycardia, pericarditis, severe changes of electrocardiogram, and myocardiopathy, nevertheless, such acute toxicity appears temporarily, and if treated, it could be recovered completely without chronic outcomes. 6 In subacute cardiotoxicity cases, it may be developed between 3 months and 8 months after the completion of chemotherapy, and it shows heart failure features primarily. In chronic cardiotoxicity, it is developed after 5 years, left ventricular function is deteriorated gradually leading to congestive heart failure, and afterward, it lasts for a long time, and thus quality of life is lowered (2,3,7,11). Therefore, it could be considered to be important to recognize the high risk patient group who may develop cardiotoxicity induced by chemotherapeutic agents, and to prevent and treat it.

Ventriculography applying echocardiogram and radioactive isotopes is a non-invasive test, and it has been applied widely to the examination of the cardiotoxicity induced by chemotherapeutic agents, nevertheless, as a test applied to the early detection of condition that cardiac condition is not completely deteriorated yet, its sensitivity is low (10).

It has been well known that plasma concentration of Brain Natriuretic Peptide (BNP) that is a type of cardiac neuronal hormone released from the ventricles by the elevation of ventricular pressure correlates significantly to the end diastolic pressure of the left ventricle and the wedge pressure of pulmonary capillary blood vessels in heart failure patients, and it reflects the dysfunction of the left ventricle pertinent to it. The avascularizatin rate of the left ventricle applying echocardiogram is an important means to observe and monitor heart failure, and it is good for the diagnosis of heart failure that has been developed already, however, it is not useful for the prediction of early cardiotoxicity. Not only plasma BNP concentration could be measured rapidly and readily, even in cases with normal avascularization rate, if the concentration were elevated, the increase of ventricular load could be suspected, and thus it could be applied as a factor that could predict early cardiotoxicity (14-19). In our study, among 86 patients, more than 60% were malignant lymphoma patients, and they received the combination chemotherapy of cyclophosphamide, vincristine, and prednisolon including anthracyclin. In adults, malignant hematological diseases are developed in relatively older patients, between the age of 50 years and 70 years, and in such cases, many patients have chronic diseases such as hypertension, diabetes, etc (12). As shown in the results, the presence or absence of accompanying chronic disease acts as an independent risk factor in the development of cardiac complications. Particularly, in the treatment of non-Hodgkins lymphoma, most cases receive combination chemotherapy including steroids such as prednisolon, and the incidence of secondary diabetes has been reported to be 10~20%, and thus it may increase the risk of the development of cardiac diseases.

Cardiac troponin has been shown to be the most sensitive and specific factor for the prediction of myocardial injury, and its usefulness is applied not only to the diagnosis of acute myocardial infarction, but also to predict the short term or long term risk level of acute coronary artery syndrome (20,21). According to some studies, in cardiotoxicity associated with the use of anthracyclin chemotherapeutic agents, serum troponin-I value has been shown to be related to the histopathological change of the myocardium, and particularly, its elevation persistent for longer than one monthe is associated not only with cardiac dysfunction that would be developed in the future, but also more serious cardiac complications (21). In our study, similarly, cardiotoxicity developed after chemotherapy showed a correlation to troponin-I.

Adriamycin and cyclophosphamide are durgs of which cardiotoxicity is well known, and recently, for cases older than 60 years, with the history of the previous use of anthracyclin, or with chronic diseases pentinent to the heart, the trend is to use liposome-encapsulated doxorubicin of which cardiotoxicity is less, and consequently, cardiotoxicity could be reduced (22). Particularly, multiple myeloma is a disease of which onset is between the late 60s and the 70s preferentially, and most patients have risk factors of cardiotoxicity, hence, attentive monitoring of the heart may be necessary.

According to the research reports performed by numerous prospective as well retrospective analysis, cardiotoxicity appears frequently in cases whose cumulative dose of anthracyclin chemotherapeutic agents is higher than 300 mg/m² or with previous cardiac diseases (4). However, in our study, in the comparison of cases whose cumulative dose was higher than 300 mg/m² with cases lower than that, the incidence of cardiotoxicity did not show a statistical difference, and among the entire 86 patients, cases whose cumulative dose was higher than 500 mg/m² were 6 patients, and cardiotoxicity was developed in 4 patients, and thus the correlation to cardiotoxicity was detected in cases whose cumulative dose of anthracyclin chemotherapeutic agents was higher than 500 mg/m².

Although not all oncologists agree, in many cases, the use of liposome type anthracyclin derivatives for patients with risk factors has been accepted and recommended (23). In several reports, it has been reported that cardiotoxicity could be reduced by the use of dextrazoxane, and iron chylators, hence, in cases using anthracyclin chemotherapeutic agents from the initial time, its use was recommended from the prophylactic aspect, nonetheless, large numbers recommend to use it on limited cases with the cumulative dose higher than 300 mg/m² (24).

Based on our results, in malignant hematological tumor patients whose long term survival is possible, for cases receiving chemotherapy including anthracyclin chemotherapeutic agents, the elevation of the concentration or value through the regular measurement of plasma BNP concentration and troponin-I may correlate to the development of cardiotoxicity, and if their abnormal findings were detected, to perform aggressive prevention and treatment for the heart may be of help to improve the long term morbidity and survival of malignant diseases of which complete cure is anticipated, and furthermore, to improve quality of life.

CONCLUSION

In patients received chemotherapy including anthracyclin chemotherapeutic agents, the elevation of serum BNP concentration is a factor associated with the development of cardiotoxicity, and to understand the more accurate cause-effect of the correlation of serum BNP concentration and the development of cardiotoxicity, it is considered that prospective clinical studies are required in the future.

REFERENCES

1. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685–7696. PMID: 16234530Article PubMed
2. Ewer M, Benjamin RS. . In: Perry MC, editor. Cardiotoxicity of chemotherapeutic drugs. The chemotherapy sourcebook. 2001. 3rd ed. Philadelphia, PA: Lippincott: Williams & Wilkins; p. 458–468.
3. Bonneterre J, Roche H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, et al. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French Adjuvant Study Group. J Clin Oncol. 2004;22:3070–3079. PMID: 15284257Article PubMed
4. Poutanen T, Tikanoja T, Riikonen P, Silvast A, Perkkio M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003;21:2349–2356. PMID: 12805337Article PubMed
5. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22:1864–1871. PMID: 15143078Article PubMed
6. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med. 1978;65:823–832. PMID: 707541Article PubMed
7. Steinherz LJ, Yahalom J. . In: DeVita VT, Hellman S, Rosenberg SA, editors. Cardiac toxicity. Cancer: principles and practice of oncology. 2001. 6th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; p. 2904–2921.
8. Theodoulou M, Seidman AD. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol. 2003;30:730–739. PMID: 14663774Article PubMed
9. Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545–550. PMID: 9469339Article PubMed
10. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461–470. PMID: 8960141Article PubMed
11. Hale ER, Lipshultz S, Constine L. Latent injury after the double-edged sword of chemo/radiation. 2005 ASCO educational book. 2005. Alexandria, VA: American Society of Clinical Oncology; p. 739–746.
12. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717. PMID: 496103Article PubMed
13. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738–1743. PMID: 7760889Article PubMed
14. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367–374. PMID: 11231433Article PubMed
15. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37:4–9. PMID: 11466716Article PubMed
16. Nousiainen T, Vanninen E, Jantunen E, Remes J, Ritanen E, Vuolteenaho O, et al. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clin Sci (Lond). 2001;101:601–607. PMID: 11724646Article PubMed
17. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol. 1999;62:135–141. PMID: 10052718Article PubMed
18. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–7826. PMID: 16258084Article PubMed
19. Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol. 2004;22:769–773. PMID: 14990630Article PubMed
20. Herman EH, Lipshultz SE, Rifai N, Zhang J, Papoian T, Yu ZX, et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. 1998;58:195–197. PMID: 9443390PubMed
21. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517–522. PMID: 10933366Article PubMed
22. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–1454. PMID: 11230490Article PubMed
23. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988;319:745–752. PMID: 3137469Article PubMed
24. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997;15:1333–1340. PMID: 9193324Article PubMed
25. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441–1446. PMID: 5122894Article PubMed

Table 1

Patient characteristics

^*blood pressure, ^†left ventricular, ^‡diabetes mellitus, ^§chronic obstructive pulmonary disease.

Table 2

Cardiac problem incidence

Table 3

BNP, LV mass, LVEF variation according to development of cardiac event

^*chemotherapy, ^†left ventricular mass, ^‡left ventricular ejection fraction. Cardiac event is defined heart failure only among the event types.

Table 4

Univariable analysis

^*Mann-Whitney test, ^†chi-square test, ^‡chemotherapy, ^§systolic blood pressure, ^∥heart rate, ^¶left ventricular mass, ^**left ventricular ejection fraction, ^††multiple myeloma, ^‡‡electrocardiography. Cardiac event is defined heart failure only among the event types.

Table 5

Multivariable analysis

^*left ventricular ejection fraction, ^†chronic disease, ^‡electrocardiography. Cardiac event is defined to heart failure only among the event types.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study
Ling-Ming Tseng, Fang Ming Chen, Shou-Tung Chen, Fiona Tsui-Fen Cheng, Tsu-Yi Chao, Ming-Shen Dai, Woei-Yau Kao, Ming-Hsin Yeh, Dar-Ren Chen, Liang-Chih Liu, Hewi Chung Wang, Hong-Tai Chang, Being Whey Wang, Jyh-Cherng Yu, Shin Cheh Chen, Guo-Shiou Liao,
Oncology Research and Treatment.2024; 47(10): 484. CrossRef
Low-Dose Radiation Reduces Doxorubicin-Induced Myocardial Injury Through Mitochondrial Pathways
Di Zhao, Xin Jiang, Xinxin Meng, Dandan Liu, Yanwei Du, Lijing Zhao, Hongyu Jiang
Dose-Response.2023;[Epub] CrossRef
Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka
Jayasinghe Arachchige Nirosha Sandamali, Ruwani Punyakanthi Hewawasam, Madappuli Arachchige Chaminda Sri S Fernando, Kamani Ayoma Perera Wijewardana Jayatilaka
BMC Cancer.2023;[Epub] CrossRef
Non-coding RNAs, cancer treatment and cardiotoxicity: A triad of new hope
Rishabh Mittal, Sarath Krishnan M P, Rahul Saxena, Ananyan Sampath, Bela Goyal
Cancer Treatment and Research Communications.2023; 36: 100750. CrossRef
Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity
Xinxin Zhang, Yuxi Sun, Yanli Zhang, Fengqi Fang, Jiwei Liu, Yunlong Xia, Ying Liu
Journal of Cardiovascular Development and Disease.2022; 9(11): 372. CrossRef
Genetic Polymorphisms Affecting Cardiac Biomarker Concentrations in Children with Cancer: an Analysis from the “European Paediatric Oncology Off-patents Medicines Consortium” (EPOC) Trial
Farina Hellmann, Swantje Völler, Miriam Krischke, David Jamieson, Nicolas André, Gianni Bisogno, Alan Boddy, Georg Hempel
European Journal of Drug Metabolism and Pharmacokinetics.2020; 45(3): 413. CrossRef
Cardiotoxicity of Anthracyclines
Daniela Cardinale, Fabiani Iacopo, Carlo Maria Cipolla
Frontiers in Cardiovascular Medicine.2020;[Epub] CrossRef
The Role of Biomarkers in Cardio-Oncology
Kajaluxy Ananthan, Alexander R. Lyon
Journal of Cardiovascular Translational Research.2020; 13(3): 431. CrossRef
Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia
Letitia Elena Radu, Roxana Corina Sfetea, Constantin Virgiliu Arion, Anca Colita
Revista Romana de Medicina de Laborator.2020; 28(2): 133. CrossRef
Oncologic therapies associated with cardiac toxicities: how to minimize the risks
Daniela Cardinale, Federica Stivala, Carlo M. Cipolla
Expert Review of Anticancer Therapy.2019; 19(5): 359. CrossRef
Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)
Rohit Moudgil, Parag A. Parekh
Heart Failure Reviews.2018; 23(2): 255. CrossRef
Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress
Faisal Imam, Naif O. Al-Harbi, Mohammed M. Al-Harbia, Hesham M. Korashy, Mushtaq Ahmad Ansari, Mohamed M. Sayed-Ahmed, Mahmoud N. Nagi, Muzaffar Iqbal, Md. Khalid Anwer, Imran Kazmi, Muhammad Afzal, Saleh Bahashwan
Cardiovascular Toxicology.2017; 17(1): 58. CrossRef
Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy
Daniela Cardinale, Gina Biasillo, Michela Salvatici, Maria Teresa Sandri, Carlo Maria Cipolla
Expert Review of Molecular Diagnostics.2017; 17(3): 245. CrossRef
Alternative Biomarkers for Combined Biology
Yong-Hyun Kim, Jennifer Kirsop, Wai Hong Wilson Tang
Heart Failure Clinics.2017; 13(2): 381. CrossRef
Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts
Gina Biasillo, Carlo M. Cipolla, Daniela Cardinale
Current Oncology Reports.2017;[Epub] CrossRef
Cardiovascular Complications of Cancer Therapy
Hui-Ming Chang, Rohit Moudgil, Tiziano Scarabelli, Tochukwu M. Okwuosa, Edward T.H. Yeh
Journal of the American College of Cardiology.2017; 70(20): 2536. CrossRef
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management
Giuseppe Curigliano, Daniela Cardinale, Susan Dent, Carmen Criscitiello, Olexiy Aseyev, Daniel Lenihan, Carlo Maria Cipolla
CA: A Cancer Journal for Clinicians.2016; 66(4): 309. CrossRef
Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress
Hesham M. Korashy, Ibraheem M. Attafi, Mushtaq A. Ansari, Mohammed A. Assiri, Osamah M. Belali, Sheik F. Ahmad, Ibrahim A. AL-Alallah, Fawaz E.Al Anazi, Abdulqader A. Alhaider
Toxicology Letters.2016; 252: 50. CrossRef
Role of biomarkers in monitoring antiblastic cardiotoxicity
Giuseppina Novo, Christian Cadeddu, Vincenzo Sucato, Pasquale Pagliaro, Silvio Romano, Carlo G. Tocchetti, Concetta Zito, Luca Longobardo, Savina Nodari, Maria Penco
Journal of Cardiovascular Medicine.2016; 17: e27. CrossRef
Biomarkers and Cancer Therapy-Related Cardiac Dysfunction
Prateek Sharma, Mahin Rehman, Javed Butler, Michelle W. Bloom
Current Cardiovascular Risk Reports.2016;[Epub] CrossRef
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy
Christine Henri, Therese Heinonen, Jean-Claude Tardif
Biomarkers in Cancer.2016; 8s2: BIC.S31798. CrossRef
Serum B-type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity
YA-DI WANG, SU-XIAN CHEN, LI-QUN REN
Oncology Letters.2016; 11(5): 3483. CrossRef
Mitogen-Activated Protein Kinases Pathways Mediate the Sunitinib-Induced Hypertrophy in Rat Cardiomyocyte H9c2 Cells
Hesham Mohamed Korashy, Hani A. Al-Suwayeh, Zaid H. Maayah, Mushtaq Ahmad Ansari, Sheikh Fayaz Ahmad, Saleh A. Bakheet
Cardiovascular Toxicology.2015; 15(1): 41. CrossRef
Cardiotoxicity due to Chemotherapy: the Role of Biomarkers
Patrick L. Stevens, Daniel J. Lenihan
Current Cardiology Reports.2015;[Epub] CrossRef
Cardiac Complications of Chemotherapy: Role of Biomarkers
Alessandro Colombo, Maria T. Sandri, Michela Salvatici, Carlo M. Cipolla, Daniela Cardinale
Current Treatment Options in Cardiovascular Medicine.2014;[Epub] CrossRef
Use of Biomarkers for the Assessment of Chemotherapy-induced Cardiac Toxicity
Eric S. Christenson, Theodore James, Vineet Agrawal, Ben H. Park
Clinical Biochemistry.2014;[Epub] CrossRef
BNP Predicts Chemotherapy-Related Cardiotoxicity and Death: Comparison with Gated Equilibrium Radionuclide Ventriculography
Dorthe Skovgaard, Philip Hasbak, Andreas Kjaer, Claudio Moretti
PLoS ONE.2014; 9(5): e96736. CrossRef
Using Cardiac Biomarkers and Treating Cardiotoxicity in Cancer
Alessandro Colombo, Daniela Cardinale
Future Cardiology.2013; 9(1): 105. CrossRef
Exaggerated NT‐proBNP Production in Patients With Hematologic Malignancies: A Case Series
Aileen Andreu, Maya Guglin
Congestive Heart Failure.2012; 18(6): 333. CrossRef
Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: A single center experience
Erkan Dogan, Hikmet Yorgun, Ibrahim Petekkaya, Necla Ozer, Kadri Altundag, Yavuz Ozisik
Medical Oncology.2012; 29(5): 3232. CrossRef
NT-ProBNP and cardiac troponin I in virulent canine babesiosis
Remo Lobetti, Robert Kirberger, Ninette Keller, Frank Kettner, Eran Dvir
Veterinary Parasitology.2012; 190(3-4): 333. CrossRef
Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo
Lidia Boccardi, Daniela Cardinale, Maurizio Civelli, Chiara Lestuzzi, Carlo Materazzo, Nicola Maurea, Ines Monte, Stefano Oliva, Patrizia Piotti, Giuseppina Quattrocchi, Elisabetta Rossi, Giuseppe Toglia
Journal of Cardiovascular Echography.2011; 21(1): 32. CrossRef
Role of biomarkers in cardioncology
Daniela Cardinale, Michela Salvatici, Maria T. Sandri
Clinical Chemistry and Laboratory Medicine (CCLM).2011;[Epub] CrossRef
Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice
Ahmed M. Al-Abd, Ki-Yun Hong, Soo-Chang Song, Hyo-Jeong Kuh
Journal of Controlled Release.2010; 142(1): 101. CrossRef
Cardiac Involvement in Patients with Hematologic Malignancies
Alessandro Allegra, Andrea Alonci, Sabina Russo, Antonino Cannavò, Giuseppa Penna, Arianna D'Angelo, Giacomo Bellomo, Caterina Musolino
Journal of Investigative Medicine.2010; 58(7): 859. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity

Cancer Res Treat. 2008;40(3):121-126. Published online September 30, 2008

DOI: https://doi.org/10.4143/crt.2008.40.3.121

XML Download

Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity

Table 1

Patient characteristics

^*blood pressure, ^†left ventricular, ^‡diabetes mellitus, ^§chronic obstructive pulmonary disease.

Table 2

Cardiac problem incidence

Table 3

BNP, LV mass, LVEF variation according to development of cardiac event

^*chemotherapy, ^†left ventricular mass, ^‡left ventricular ejection fraction. Cardiac event is defined heart failure only among the event types.

Table 4

Univariable analysis

Table 5

Multivariable analysis

^*left ventricular ejection fraction, ^†chronic disease, ^‡electrocardiography. Cardiac event is defined to heart failure only among the event types.

Table 1 Patient characteristics

^*blood pressure, ^†left ventricular, ^‡diabetes mellitus, ^§chronic obstructive pulmonary disease.

Table 2 Cardiac problem incidence

Table 3 BNP, LV mass, LVEF variation according to development of cardiac event

^*chemotherapy, ^†left ventricular mass, ^‡left ventricular ejection fraction. Cardiac event is defined heart failure only among the event types.

Table 4 Univariable analysis

Table 5 Multivariable analysis

^*left ventricular ejection fraction, ^†chronic disease, ^‡electrocardiography. Cardiac event is defined to heart failure only among the event types.